Psychosocial dysfunction in the first year after Guillain–Barré syndrome

Bernsen, R.A.J.A.M.; Jager, A.E.J. de; Kuijer, Wietske; Meché, F. G. A. Van Der; Suurmeijer, T

doi:10.1002/mus.21536

Cited by 31 publications

(27 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another group investigated psychological distress, depressive symptoms, and the health status of patients during the first year after a diagnosis of GBS [25]. At 3, 6 and 12 months post-diagnosis, patients (n = 85) were administered the General Health Questionnaire, Sickness Impact Profile, and Center for Epidemiologic Studies Depression Scale.…”

Section: Anxiety/depression In Immune-mediated Neuropathiesmentioning

confidence: 99%

Fatigue, Pain, Anxiety and Depression in Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Merkies

Kieseier²

2016

Eur Neurol

608

View full text Add to dashboard Cite

Background: In the clinical evaluation of patients with Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), scant attention is paid to symptoms such as fatigue, pain and anxiety/depression. We aimed at addressing seminal studies that focused on the burden of these symptoms and their impact on quality of life (QoL) in these conditions. Summary: Fatigue, pain, and anxiety/depression are increasingly being recognized in patients with GBS and CIDP, although their pathophysiological provenance remains unknown. Fatigue and pain are significant in terms of prevalence and intensity, may be a presenting symptom, and can persist for years after apparent functional recovery, suggesting residual injury. Anxiety/depression has also been examined although studies are limited. Despite their negative impact on QoL, the long-term dynamics of these symptoms in patients with GBS and particularly CIDP receiving therapy in routine clinical practice have not been systematically evaluated. Such observations formed the basis for the ongoing (GAMEDIS) studies evaluating the effect of Gamunex® on fatigue and depression in patients with CIDP, of which some preliminary data are presented. Key Messages: Strength and sensory deficits are the main areas of focus in patients with GBS and CIDP, but they do not explain the total reduction in QoL, suggesting the possible role of other complaints. A more comprehensive approach to patient care demands that factors such as pain, fatigue and anxiety/depression receive greater attention. The non-interventional GAMEDIS studies are expected to provide valuable insight into the long-term effectiveness of Gamunex® in everyday practice.

show abstract

Section: Anxiety/depression In Immune-mediated Neuropathiesmentioning

confidence: 99%

Fatigue, Pain, Anxiety and Depression in Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Merkies

Kieseier²

2016

Eur Neurol

608

View full text Add to dashboard Cite

show abstract

“…Similarly, depression and stress appear to be more frequent in patients with a history of GBS, even years after the acute episode . There is some uncertainty about the duration of psychological distress in view of findings by Bernsen et al . Both anxiety and depression may correlate with the presence of neurological disability and persistence of minor symptoms affecting patient well‐being, even in the presence of complete recovery from GBS, although there has been no consistency of findings in this regard .…”

Section: Discussionmentioning

confidence: 98%

Neuropsychiatric manifestations in inflammatory neuropathies: A systematic review

2016

View full text Add to dashboard Cite

We conducted a systematic literature review on psychological and behavioral comorbidities in patients with inflammatory neuropathies. In Guillain–Barré syndrome (GBS), psychotic symptoms are reported during early stages in 30% of patients. Typical associations include mechanical ventilation, autonomic dysfunction, inability to communicate, and severe weakness. Anxiety and depression are frequent comorbidities. Anxiety may increase post‐hospital admissions and be a predictor of mechanical ventilation. Posttraumatic stress disorder may affect up to 20% of ventilated patients. Sleep disturbances are common in early‐stage GBS, affecting up to 50% of patients. In chronic inflammatory demyelinating polyradiculoneuropathy, memory and quality of sleep may be impaired. An independent link between depression and pretreatment upper limb disability and ascites was reported in POEMS (polyneuropathy, organomegaly, endocrinopathy, M‐protein, skin) syndrome, with an association with early death. Hematological treatment of POEMS appears effective on depression. Published literature on psychological/behavioral manifestations in inflammatory neuropathies remains scarce, and further research is needed. Muscle Nerve 54: 1–8, 2016

show abstract

“…The lack of correlation of the functional subset with the EQ-VAS could be due to the fact patients rating their ‘health quality’ mostly based on their mental impact and insecurity rather than their ‘functional’ health 30. Also, for example, in patients with GBS and CIDP, functional recovery does not necessarily imply a good health quality due to residual complaints like fatigue, pain, depression, and so on which is a known common complaint in these patients 30–33…”

Section: Discussionmentioning

confidence: 99%